Prognostic value of MT1 receptor in breast tumor lines

• Grant number: 17/01514-9
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: June 01, 2017
• End date: November 30, 2018
• Field of knowledge: Biological Sciences - Genetics - Human and Medical Genetics
• Principal Investigator: Debora Aparecida Pires de Campos Zuccari
• Grantee: Fabrício Valiante Ventura
• Host Institution: Faculdade de Medicina de São José do Rio Preto (FAMERP). Secretaria de Desenvolvimento Econômico (São Paulo - Estado). São José do Rio Preto , SP, Brazil

Abstract

Breast cancer is the most prevalent neoplasm and mortality in women worldwide, and in 2016 it was estimated that 57,960 new cases occurred in Brazil. Current diagnostic methods are mainly limited to invasive procedures, and even after diagnosis, prognostic determination may not be conclusive, as patients may gain resistance to treatment, favoring tumor growth, invasion, and metastasis. Thus, prognostic markers can be used to determine tumor characteristics, identifying patients who will benefit from specific treatments. Melatonin has repeatedly been shown to be a growth inhibitor of breast tumor cells, but its anti-proliferative effect on estrogen receptor positive cells such as the MCF-7 lineage is much higher when compared to triple-negative cells, such as To MDA-MB-231. Melatonin can act by means of membrane receptors coupled to protein G, called MT1 and MT2. Thus, it is suggested that the lower response to the melatonin suppressor effect on MDA-MB-231 cells is due to lower MT1 receptor expression. The aim of this study was to evaluate the expression of the MT1 receptor in human breast cancer cells (MCF-7, MDA-MB-231, MDA-MB-468) and canine (CF-41 and CMT-U229 ) Relating the results based on the different molecular subtypes of the lineages, and thus infer its value as a diagnostic and prognostic marker.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

CUSTODIO, PAULO R.; COLOMBO, JUCIMARA; VENTURA, FABRICIO V.; CASTRO, TIAL B.; ZUCCARI, DEBORA A. P. C.. Melatonin Treatment Combined with TGF-beta Silencing Inhibits Epithelial-Mesenchymal Transition in CF41 Canine Mammary Cancer Cell Line. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, v. 20, n. 8, p. 989-997, 2020. (17/01514-9)

CUSTODIO, PAULO R.; COLOMBO, JUCIMARA; VENTURA, FABRICIO V.; CASTRO, TIAL B.; ZUCCARI, DEBORA A. P. C.. Melatonin Treatment Combined with TGF-β Silencing Inhibits Epithelial-Mesenchymal Transition in CF41 Canine Mammary Cancer Cell Line. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, v. 20, n. 8, p. 9-pg., 2020-01-01. (17/01514-9)